The mazda pharma Guide 12th August to 18th August 2013 | Page 61
?AR M AC ? P H
with a US FDA approved facility and immediate access to the regulated markets. There are also compelling forward integration synergies for Vivimed's existing API business and formulations dossier development activities. Along with the facility, we have acquired two commercially valuable and marketable ANDAs which we believe, will allow us to generate additional revenues. We agreement with the Actavis Group for a defined period which will also be a source of revenue for us. The transaction has been structured attractively at a low net cash consideration for Vivimed.” The current capacity of the facility is 1.2 billion SOD per annum. The facility is located on a five acre site of which three acres are currently unutilized. Vivimed eventually plans to meaningfully expand APMPL's current manufacturing capacities over the medium term. This acquisition provides Vivimed with immediate finished dosage formulations (FDF) access to the US, the largest generics market in the world. In addition, this US FDA approved facility is a natural extension for Vivimed's manufacturing platform which currently only caters to the FDF semiregulated markets.
E U TIC
AL N
E W S
of research, originality and novelty etc. The seminar was presided over by Dr Bharat Chhaparwal, ex. vice-chancellor, Devi Ahilya Vishwavidyalaya (Indore), Dr Vinod Bhandari, chairman, Sri Aurobindo Group of Institutions, Indore and Prof. S C Chaturvedi, director of Sri Aurobindo Institute of Pharmacy welcomed about 250 delegates hailing from different colleges across the country, mostly from central India. Experts from across the country were present at the national event held at the institute. Prof. C T Chopde, ex professor and head, Department of Pharmaceutical Sciences, Nagpur University, Nagpur, discussed “Clinical research in India: From boon to bane or rebound? Impact of regulatory reforms” which paved the way to better understanding of ethical framework, ethical principal of Indian GCP, CDSCO compliance & guidelines, Supreme court directives, schedule Y, form 122A, Form 122B, stringency ????????????????????????????A????L?M??????????????????????????????U???????9??????U???A???????????????????????????????????q???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????A????L?,?-????????????????????????A???????????????????????????????????????U????????%???????????A??????U????????
?????????????????? ???????-??????????????????????????????????????qA????????????????????????%??????A?A$??????t???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????%????????????????????????????????????????????????????????????????()??????????????????????????????????????????????????????????????????????????????????????????????????????%?????????????????